文献速递甲状腺疾病

Afirma GSC与Xpression Atlas在连续Bethesda III-VI甲状腺结节中的分子发现

Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该研究回顾性分析50 644个连续Bethesda III-VI甲状腺细针穿刺样本的RNA测序数据,评估Afirma GSC与XA检测的分子结果。48 952个Bethesda III/IV样本中66%经GSC判为良性;BRAF V600E在Bethesda III/IV中占2%,Bethesda VI中占76%。NTRK/RET融合阳性预测值>95%,BRAF和ALK融合分别为81%和67%。

要点

  • Bethesda III/IV中66%经Afirma GSC判为良性,BRAF V600E仅占2%。
  • NTRK或RET融合对癌或NIFTP的阳性预测值>95%,BRAF和ALK融合分别为81%和67%。
  • Bethesda V/VI结节中多数可检出至少1种基因组变异或融合。

核心结论

  • 近半数Bethesda III/IV Afirma GSC可疑结节及多数Bethesda V/VI结节至少检出1种基因组变异或融合。

研究设计与样本

  • 回顾性分析RNA测序数据文件,纳入50 644个连续Bethesda III-VI甲状腺细针穿刺样本。

主要发现

  • 48 952个Bethesda III/IV样本中66%经Afirma GSC判为良性。
  • BRAF V600E在全部Bethesda III/IV中占2%,在Bethesda VI中占76%。
  • NTRK、RET、BRAF和ALK融合在Bethesda V中最常见,占10%,并发现130种不同基因伴侣。
  • 在有小样本连续Bethesda III/IV队列及手术病理数据中,NTRK或RET融合对癌或NIFTP的阳性预测值>95%,BRAF融合为81%,ALK融合为67%。
  • 扩展Afirma XA panel在70%甲状腺髓样癌分类器阳性、44% Bethesda III/IV GSC可疑、64% Bethesda V和87% Bethesda VI样本中检出至少1种基因组改变。

临床怎么用

  • Afirma GSC可用于Bethesda III/IV结节的良性判断,减少不必要的手术。
  • Afirma XA检出的融合类型可辅助Bethesda III-VI结节的个体化治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Broad genomic analyses among thyroid histologies have been described from relatively small cohorts. OBJECTIVE: Investigate the molecular findings across a large, real-world cohort of thyroid fine-needle aspiration (FNA) samples. DESIGN: Retrospective analysis of RNA sequencing data files. SETTING: Clinical Laboratory Improvement Amendments laboratory performing Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas (XA) testing. PARTICIPANTS: A total of 50 644 consecutive Bethesda III-VI nodules. INTERVENTION: None. MAIN OUTCOME MEASURES: Molecular test results. RESULTS: Of 48 952 Bethesda III/IV FNAs studied, 66% were benign by Afirma GSC. The prevalence of BRAF V600E was 2% among all Bethesda III/IV FNAs and 76% among Bethesda VI FNAs. Fusions involving NTRK, RET, BRAF, and ALK were most prevalent in Bethesda V (10%), and 130 different gene partners were identified. Among small consecutive Bethesda III/IV sample cohorts with one of these fusions and available surgical pathology excision data, the positive predictive value of an NTRK or RET fusion for carcinoma or noninvasive follicular thyroid neoplasm with papillary-like nuclear features was >95%, whereas for BRAF and ALK fusions it was 81% and 67%, respectively. At least 1 genomic alteration was identified by the expanded Afirma XA panel in 70% of medullary thyroid carcinoma classifier-positive FNAs, 44% of Bethesda III or IV Afirma GSC suspicious FNAs, 64% of Bethesda V FNAs, and 87% of Bethesda VI FNAs. CONCLUSIONS: This large study demonstrates that almost one-half of Bethesda III/IV Afirma GSC suspicious and most Bethesda V/VI nodules had at least 1 genomic variant or fusion identified, which may optimize personalized treatment decisions.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Hu MI, Waguespack SG, Dosiou C, et al. Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules. J Clin Endocrinol Metab. 2021. PMID: 34009369. doi:10.1210/clinem/dgab304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。